FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322207925> ?p ?o ?g. }

• W4322207925 endingPage "378" @default.
• W4322207925 startingPage "369" @default.
• W4322207925 abstract "First-line treatment options for patients with advanced non-small cell lung cancer (aNSCLC) whose tumors harbour anaplastic lymphoma kinase (ALK) gene rearrangements have rapidly evolved from chemotherapy, to the first in class ALK-targeted tyrosine kinase inhibitor (TKI) crizotinib in 2011, and now include no fewer than five Food and Drug Administration (FDA)-approved ALK inhibitors. However, while superiority to crizotinib has been established, head-to-head clinical trials comparing newer generation ALK inhibitors are lacking, and decisions on optimal first-line treatment must be based on analysis of the relevant trials, with attention to systemic and intracranial efficacy, toxicity profile as well as consideration of patient factors and preferences. Here we aim to synthesise findings from review of these trials and to describe options for optimal first-line treatment for ALK+ NSCLC.A literature review of relevant randomised clinical trials was undertaken using Embase database. There were no limitations to time frame or language applied.Crizotinib was established as the standard of care first-line treatment for patients with ALK+ aNSCLC in 2011. Since this time, alectinib, brigatinib, ensartinib and lorlatinib have all demonstrated superiority as first-line treatments compared to crizotinib, based on progression free survival, intra-cranial efficacy, and side-effect profiles.Options for optimal first-line treatment for ALK+ aNSCLC include alectinib, brigatinib and lorlatinib. This review serves as a resource summarizing data from key clinical trials with ALK inhibitors to aid in decision making when tailoring treatment for patients. Future research in the field includes real world analysis of efficacy and toxicity of next-generation ALK-inhibitors, identification of mechanisms of tumor persistence and acquired resistance, development of novel ALK inhibitors, and use of ALK-TKIs in earlier stage disease." @default.
• W4322207925 created "2023-02-27" @default.
• W4322207925 creator A5052608673 @default.
• W4322207925 creator A5056722994 @default.
• W4322207925 date "2023-02-01" @default.
• W4322207925 modified "2023-10-01" @default.
• W4322207925 title "Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer—a narrative review" @default.
• W4322207925 cites W1744290301 @default.
• W4322207925 cites W1871221741 @default.
• W4322207925 cites W1964370859 @default.
• W4322207925 cites W1964973266 @default.
• W4322207925 cites W2041835001 @default.
• W4322207925 cites W2050249255 @default.
• W4322207925 cites W2055402151 @default.
• W4322207925 cites W2099530756 @default.
• W4322207925 cites W2116478428 @default.
• W4322207925 cites W2125735484 @default.
• W4322207925 cites W2134787029 @default.
• W4322207925 cites W2147038864 @default.
• W4322207925 cites W2151116840 @default.
• W4322207925 cites W2212335550 @default.
• W4322207925 cites W2482427906 @default.
• W4322207925 cites W2581996620 @default.
• W4322207925 cites W2613260339 @default.
• W4322207925 cites W2624310346 @default.
• W4322207925 cites W2734805455 @default.
• W4322207925 cites W2796631032 @default.
• W4322207925 cites W2803802743 @default.
• W4322207925 cites W2805354595 @default.
• W4322207925 cites W2887380463 @default.
• W4322207925 cites W2894476389 @default.
• W4322207925 cites W2899668190 @default.
• W4322207925 cites W2922836343 @default.
• W4322207925 cites W2923683745 @default.
• W4322207925 cites W2926335811 @default.
• W4322207925 cites W2939690516 @default.
• W4322207925 cites W2991627091 @default.
• W4322207925 cites W3002978961 @default.
• W4322207925 cites W3007665819 @default.
• W4322207925 cites W3011515154 @default.
• W4322207925 cites W3022131485 @default.
• W4322207925 cites W3093085210 @default.
• W4322207925 cites W3101089668 @default.
• W4322207925 cites W3200994971 @default.
• W4322207925 cites W4226257711 @default.
• W4322207925 cites W4281289792 @default.
• W4322207925 cites W4283796071 @default.
• W4322207925 cites W4285384696 @default.
• W4322207925 doi "https://doi.org/10.21037/tlcr-22-656" @default.
• W4322207925 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36895924" @default.
• W4322207925 hasPublicationYear "2023" @default.
• W4322207925 type Work @default.
• W4322207925 citedByCount "3" @default.
• W4322207925 countsByYear W43222079252023 @default.
• W4322207925 crossrefType "journal-article" @default.
• W4322207925 hasAuthorship W4322207925A5052608673 @default.
• W4322207925 hasAuthorship W4322207925A5056722994 @default.
• W4322207925 hasBestOaLocation W43222079251 @default.
• W4322207925 hasConcept C117643217 @default.
• W4322207925 hasConcept C126322002 @default.
• W4322207925 hasConcept C143998085 @default.
• W4322207925 hasConcept C2776232967 @default.
• W4322207925 hasConcept C2776256026 @default.
• W4322207925 hasConcept C2778347629 @default.
• W4322207925 hasConcept C2779220645 @default.
• W4322207925 hasConcept C2779422266 @default.
• W4322207925 hasConcept C2779750558 @default.
• W4322207925 hasConcept C535046627 @default.
• W4322207925 hasConcept C71924100 @default.
• W4322207925 hasConceptScore W4322207925C117643217 @default.
• W4322207925 hasConceptScore W4322207925C126322002 @default.
• W4322207925 hasConceptScore W4322207925C143998085 @default.
• W4322207925 hasConceptScore W4322207925C2776232967 @default.
• W4322207925 hasConceptScore W4322207925C2776256026 @default.
• W4322207925 hasConceptScore W4322207925C2778347629 @default.
• W4322207925 hasConceptScore W4322207925C2779220645 @default.
• W4322207925 hasConceptScore W4322207925C2779422266 @default.
• W4322207925 hasConceptScore W4322207925C2779750558 @default.
• W4322207925 hasConceptScore W4322207925C535046627 @default.
• W4322207925 hasConceptScore W4322207925C71924100 @default.
• W4322207925 hasIssue "2" @default.
• W4322207925 hasLocation W43222079251 @default.
• W4322207925 hasLocation W43222079252 @default.
• W4322207925 hasLocation W43222079253 @default.
• W4322207925 hasOpenAccess W4322207925 @default.
• W4322207925 hasPrimaryLocation W43222079251 @default.
• W4322207925 hasRelatedWork W1981743826 @default.
• W4322207925 hasRelatedWork W2036099482 @default.
• W4322207925 hasRelatedWork W2319183095 @default.
• W4322207925 hasRelatedWork W2337452654 @default.
• W4322207925 hasRelatedWork W2533300620 @default.
• W4322207925 hasRelatedWork W2624310346 @default.
• W4322207925 hasRelatedWork W2893455974 @default.
• W4322207925 hasRelatedWork W2951367982 @default.
• W4322207925 hasRelatedWork W2987457019 @default.
• W4322207925 hasRelatedWork W3044516145 @default.
• W4322207925 hasVolume "12" @default.
• W4322207925 isParatext "false" @default.

• next